The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Allergan Generics
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
Assets owned by GlaxoSmithKline plc
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
Divestment assets of Ball and Rexam
Advised Ball Corporation on the acquisition of Rexam plc and provided a fairness opinion to the Board of Directors of Ball Corporation on the sale of select metal beverage can assets in Europe, Brazil and the United States to satisfy certain regulatory requirements in connection with its proposed acquisition of Rexam
COOEC Fluor Heavy Industries Co., Ltd.
Advised Fluor Corporation on its $489 million investment for a 49% interest in a joint venture with Offshore Oil Engineering Co., Ltd. (COOEC) to own, operate and manage the Zhuhai Fabrication Yard in China’s Guangdong province
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
Programmed Maintenance Services Limited
Advised PERSOL HOLDINGS, one of Japan’s largest HR service companies, on its acquisition of ASX-listed Programmed Maintenance Services, a leading Australian and New Zealand based provider of staffing and maintenance services
Brambles (CHEP China)
Adviser to Brambles on the merger of its China business (CHEP China) with Loscam Greater China
Mandala Multifinance
Advised JG Motor and certain other shareholders on the sale of Mandala Multifinance, a leading consumer finance company listed in Indonesia to MUFG and Adira Finance
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
MSF Sugar
Advised MSF Sugar, Australia’s third largest producer and second largest exporter of sugar, on an acquisition proposal from Mitr Phol Sugar Corp. of Thailand at an offer value of ~31% premium to previous close
Taro Pharmaceutical Industries
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
Inenco Group Pty Ltd
Advised Inenco Group Pty Ltd, one of Australasia’s leading industrial distributors, on the partial sale to Genuine Parts Company, a global distributor of automotive and industrial products
Rothschilds Continuation Holdings
held by Royal & Sun Alliance
Advised Royal & Sun Alliance on the sale of its 21.5% shareholding in Rothschilds Continuation Holdings AG to Jardine Strategic Holdings
Hitachi's Automotive Lithium-Ion Battery Business
Advised Hitachi, a leading global industrial conglomerate, on the sale of its LiB business including Hitachi Vehicle Energy
British Council’s Indian IELTS operations
Sole financial adviser to IDP Education, a co-owner and distributor of the IELTS English language test, on the acquisition of the British Council’s Indian IELTS operations
Nihon Nohyaku Co., Ltd.
Advised ADEKA Corporation, a global chemical manufacturer, on the acquisition of 51% stake of Nihon Nohyaku via the combination of the Tender Offer and Capital Injection
Japan Medical Dynamic Marketing
Advising Mitsui Chemicals, one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG
Park Electrochemical (Electronics Business)
Advised Park Electrochemical, a leading high-performance electronics materials manufacturer, on the sale of its Electronics Business to AGC Inc.
Equity stake in Bupa Arabia
Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia
Nuplex Industries’ Specialties and Masterbatch businesses
Advised Nuplex Industries, a dual listed (ASX/NZX) global manufacturer, developer and distributor of resins and additives, on the sale of its specialty chemicals and masterbatch businesses to CHAMP Private Equity, a leading Australian private equity firm
WEGU Holding GmbH
Advised the shareholders of WEGU Holding GmbH, a German provider of anti-vibration solutions and light-weight components for the automotive and truck industries, on the sale of the Company to Anhui Zhongding Sealing Parts, a Chinese listed company that makes and sells rubber sealing parts and other rubber products
Champion Flour Limited
Advised Goodman Fielder, a leading Australian listed food company, on the sale of its New Zealand flour milling business, Champion Flour, to Nisshin Seifun Group Inc.
Drakkar Holdings SA (Adisseo Group)
Advised CVC Capital Partners on the divestiture of Adisseo via the sale of Drakkar Holdings SA to China National BlueStar, a subsidiary of state-owned diversified chemicals company China National Chemical Corporation. Adisseo is a leading player in the animal nutrition market
MorphoSys AG
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
Kyowa Kirin International’s established medicines business
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company